<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39300811</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Prevalence and risk factors of long COVID among maintenance hemodialysis patients post SARS-CoV-2 infection: A one-year follow-up study in China.</ArticleTitle><Pagination><StartPage>e29932</StartPage><MedlinePgn>e29932</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29932</ELocationID><Abstract><AbstractText>Patients undergoing maintenance hemodialysis (MHD) are a high-risk group susceptible to SARS-CoV-2 infection and long-COVID syndrome appearance. However, there is limited and unclear evidence for long COVID in MHD patients. We collected the general information, symptoms, signs and laboratory indices of 366 MHD patients infected with COVID-19 and conducted 12 months follow-up with a series of questionnaires. As a result, 285 MHD patients had long COVID, with the most common symptoms were fatigue (84.69%) and muscle weakness (72.45%). Mobility problem (p&#x2009;&lt;&#x2009;0.001), anxiety/depression (p&#x2009;=&#x2009;0.002) and breathlessness (p&#x2009;&lt;&#x2009;0.001) were more prevalent in long COVID patients than in non-long COVID patients. Persistent long COVID people were more likely to report all domains problems of the EQ-5D-5L. Age, female, inadequate dialysis (Kt/V&#x2009;&lt;&#x2009;1.2), coagulation abnormalities (d-dimer&#x2009;&gt;&#x2009;1&#x2009;mg/L) and more comorbidities were risk factors for the development of long COVID. In addition to these factors, elevated inflammatory markers (CRP&#x2009;&gt;&#x2009;10&#x2009;mg/L) represent an extra risk factor for the persistence of long COVID symptoms in MHD patients. And more than 80% of long COVID symptoms would resolve after 1 year in MHD patients, of which the sixth month after COVID-19 infection is a critical turning point. In conclusion, more than 68% of MHD patients have long COVID, which has a poor impact on their health status and quality of life. These risk factors for the development and persistence of long COVID deserve the attention of clinicians.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xue</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-9483-1678</Identifier><AffiliationInfo><Affiliation>Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Linhui</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Zhumei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hongli</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Limin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82301749</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82170755</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">long&#x2010;COVID</Keyword><Keyword MajorTopicYN="N">maintenance hemodialysis</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>21</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>21</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39300811</ArticleId><ArticleId IdType="doi">10.1002/jmv.29932</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>World Health Organization. Number of COVID&#x2010;19 cases reported to WHO (cumulative total), 2024. https://data.who.int/dashboards/covid19/cases?n=c</Citation></Reference><Reference><Citation>World Health Organization. Post COVID&#x2010;19 condition (Long COVID).2022. Retrieved December 7, 2022, from https://www.who.int/europe/news-room/fact-sheets/item/post-COVID-19-condition</Citation></Reference><Reference><Citation>Szabo S, Zayachkivska O, Hussain A, Muller V. What is really &#x2018;Long COVID&#x2019;? Inflammopharmacology. 2023;31(2):551&#x2010;557. doi:10.1007/s10787-023-01194-0</Citation></Reference><Reference><Citation>Matt B, Piotr P, Daniel A Prevalence of ongoing symptoms following coronavirus (COVID&#x2010;19) infection in the UK: 2 February 2023. 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2february2023</Citation></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Network Open. 2022;5(10):e2238804. doi:10.1001/jamanetworkopen.2022.38804</Citation></Reference><Reference><Citation>National Center for Health Statistics USCB. (2023). Household pulse survey long COVID. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm</Citation></Reference><Reference><Citation>Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID&#x2010;19 survivors in Wuhan, China: A single&#x2010;centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89&#x2010;95. doi:10.1016/j.cmi.2020.09.023</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6&#x2010;month consequences of COVID&#x2010;19 in patients discharged from hospital: A cohort study. Lancet. 2023;401(10393):e21&#x2010;e33. doi:10.1016/s0140-6736(23)00810-3</Citation></Reference><Reference><Citation>Yang X, Hou C, Shen Y, et al. Two&#x2010;year health outcomes in hospitalized COVID&#x2010;19 survivors in China. JAMA Network Open. 2022;5(9):e2231790. doi:10.1001/jamanetworkopen.2022.31790</Citation></Reference><Reference><Citation>Cai J, Lin K, Zhang H, et al. A one&#x2010;year follow&#x2010;up study of systematic impact of long COVID symptoms among patients post SARS&#x2010;CoV&#x2010;2 omicron variants infection in Shanghai, China. Emerg Microbes Infect. 2023;12(2):2220578. doi:10.1080/22221751.2023.2220578</Citation></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS&#x2010;CoV&#x2010;2. Lancet. 2022;399(10343):2263&#x2010;2264. doi:10.1016/s0140-6736(22)00941-2</Citation></Reference><Reference><Citation>Pazukhina E, Andreeva M, Spiridonova E, et al. Prevalence and risk factors of post&#x2010;COVID&#x2010;19 condition in adults and children at 6 and 12&#x2009;months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Med. 2022;20(1):244. doi:10.1186/s12916-022-02448-4</Citation></Reference><Reference><Citation>Bowe B, Xie Y, Al&#x2010;Aly Z. Acute and postacute sequelae associated with SARS&#x2010;CoV&#x2010;2 reinfection. Nat Med. 2022;28(11):2398&#x2010;2405. doi:10.1038/s41591-022-02051-3</Citation></Reference><Reference><Citation>Demiray A, Kanbay A, Kanbay M. Long&#x2010;term effect of COVID&#x2010;19 infection on hemodialysis patients: Should we follow hemodialysis patients more closely? Clin Kidney J. 2022;15(3):369&#x2010;371. doi:10.1093/ckj/sfab265</Citation></Reference><Reference><Citation>Flythe JE, Assimon MM, Tugman MJ, et al. Characteristics and outcomes of individuals with pre&#x2010;existing kidney disease and COVID&#x2010;19 admitted to intensive care units in the United States. Am J Kidney Dis. 2021;77(2):190&#x2010;203.e1. doi:10.1053/j.ajkd.2020.09.003</Citation></Reference><Reference><Citation>De Meester J, De Bacquer D, Naesens M, Meijers B, Couttenye MM, De Vriese AS. Incidence, characteristics, and outcome of COVID&#x2010;19 in adults on kidney replacement therapy: A regionwide registry study. J Am Soc Nephrol. 2021;32(2):385&#x2010;396. doi:10.1681/asn.2020060875</Citation></Reference><Reference><Citation>Carriazo S, Mas&#x2010;Fontao S, Seghers C, et al. Increased 1&#x2010;year mortality in haemodialysis patients with COVID&#x2010;19: A prospective, observational study. Clin Kidney J. 2021;15(3):432&#x2010;441. doi:10.1093/ckj/sfab248</Citation></Reference><Reference><Citation>Chawki S, Buchard A, Sakhi H, et al. Long&#x2010;term impact of COVID&#x2010;19 among maintenance haemodialysis patients. Clin Kidney J. 2022;15(2):262&#x2010;268. doi:10.1093/ckj/sfab166</Citation></Reference><Reference><Citation>Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580&#x2010;586. doi:10.1378/chest.93.3.580</Citation></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five&#x2010;level version of EQ&#x2010;5D (EQ&#x2010;5D&#x2010;5L). Qual Life Res. 2011;20(10):1727&#x2010;1736. doi:10.1007/s11136-011-9903-x</Citation></Reference><Reference><Citation>Rabin Rde Charro F. EQ&#x2010;5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337&#x2010;343. doi:10.3109/07853890109002087</Citation></Reference><Reference><Citation>Chancharoenthana W, Kamolratanakul S, Leelahavanichkul A, et al. Gastrointestinal manifestations of long&#x2010;term effects after COVID&#x2010;19 infection in patients with dialysis or kidney transplantation: An observational cohort study. World J Gastroenterol. 2023;29(19):3013&#x2010;3026. doi:10.3748/wjg.v29.i19.3013</Citation></Reference><Reference><Citation>Stepanova N, Korol L, Ostapenko T, et al. Pre&#x2010;infection nutritional status, oxidative stress, and one&#x2010;year&#x2010;long COVID persistence in patients undergoing hemodialysis: A prospective cohort study. Clin Pract. 2024;14(3):892&#x2010;905. doi:10.3390/clinpract14030070</Citation></Reference><Reference><Citation>Arjun MC, Singh AK, Roy P, et al. Long COVID following Omicron wave in Eastern India&#x2014;A retrospective cohort study. J Med Virol. 2023;95(1):e28214. doi:10.1002/jmv.28214</Citation></Reference><Reference><Citation>Du M, Ma Y, Deng J, Liu M, Liu J. Comparison of long COVID&#x2010;19 caused by different SARS&#x2010;CoV&#x2010;2 strains: A systematic review and meta&#x2010;analysis. Int J Environ Res Public Health. 2022;19(23):16010. doi:10.3390/ijerph192316010</Citation></Reference><Reference><Citation>Wu J, Li J, Zhu G, et al. Clinical features of maintenance hemodialysis patients with 2019 novel coronavirus&#x2010;infected pneumonia in Wuhan, China. Clin J Am Soc Nephrol. 2020;15(8):1139&#x2010;1145. doi:10.2215/cjn.04160320</Citation></Reference><Reference><Citation>Ashby DR, Caplin B, Corbett RW, et al. Outcome and effect of vaccination in SARS&#x2010;CoV&#x2010;2 Omicron infection in hemodialysis patients: A cohort study. Nephrol Dial Transplant. 2022;37(10):1944&#x2010;1950. doi:10.1093/ndt/gfac209</Citation></Reference><Reference><Citation>Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol Metab. 2023;34(6):321&#x2010;344. doi:10.1016/j.tem.2023.03.002</Citation></Reference><Reference><Citation>Blomberg B, Mohn KGI, Brokstad KA, et al. Long COVID in a prospective cohort of home&#x2010;isolated patients. Nat Med. 2021;27(9):1607&#x2010;1613. doi:10.1038/s41591-021-01433-3</Citation></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID&#x2010;19&#x2010;related death using OpenSAFELY. Nature. 2020;584(7821):430&#x2010;436. doi:10.1038/s41586-020-2521-4</Citation></Reference><Reference><Citation>Belkacemi M, Baouche H, Gomis S, Lassalle M, Couchoud C. Long&#x2010;lasting clinical symptoms 6 months after COVID&#x2010;19 infection in the French national cohort of patients on dialysis. J Nephrol. 2022;35(3):787&#x2010;793. doi:10.1007/s40620-022-01295-z</Citation></Reference><Reference><Citation>Och A, Tylicki P, Polewska K, et al. Persistent post&#x2010;COVID&#x2010;19 syndrome in hemodialyzed patients&#x2014;A longitudinal cohort study from the North of Poland. J Clin Med. 2021;10(19):4451. doi:10.3390/jcm10194451</Citation></Reference><Reference><Citation>Fumagalli C, Zocchi C, Tassetti L, et al. Factors associated with persistence of symptoms 1 year after COVID&#x2010;19: A longitudinal, prospective phone&#x2010;based interview follow&#x2010;up cohort study. Eur J Intern Med. 2022;97:36&#x2010;41. doi:10.1016/j.ejim.2021.11.018</Citation></Reference><Reference><Citation>Merza MA, Almufty HB, Younis HA, Rasool SO, Mohammed SA. Memory impairment among recovered COVID&#x2010;19 patients: The prevalence and risk factors, a retrospective cohort study. J Med Virol. 2023;95(2):e28459. doi:10.1002/jmv.28459</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;Las&#x2010;Pe&#xf1;as C, Cancela&#x2010;Cilleruelo I, Rodr&#xed;guez&#x2010;Jim&#xe9;nez J, et al. Trajectory of post&#x2010;COVID brain fog, memory loss, and concentration loss in previously hospitalized COVID&#x2010;19 survivors: The LONG&#x2010;COVID&#x2010;EXP multicenter study. Front Hum Neurosci. 2023;17:1259660. doi:10.3389/fnhum.2023.1259660</Citation></Reference><Reference><Citation>Chu NM, Hong J, Harasemiw O, et al. Chronic kidney disease, physical activity and cognitive function in older adults&#x2014;results from the National Health And Nutrition Examination Survey (2011&#x2013;2014). Nephrol Dial Transplant. 2022;37(11):2180&#x2010;2189. doi:10.1093/ndt/gfab338</Citation></Reference><Reference><Citation>O'Lone E, Connors M, Masson P, et al. Cognition in people with end&#x2010;stage kidney disease treated with hemodialysis: A systematic review and meta&#x2010;analysis. Am J Kidney Dis. 2016;67(6):925&#x2010;935. doi:10.1053/j.ajkd.2015.12.028</Citation></Reference><Reference><Citation>Basic&#x2010;Jukic N, Juric I, Furic&#x2010;Cunko V, et al. Follow&#x2010;up of renal transplant recipients after acute COVID&#x2010;19&#x2014;A prospective cohort single&#x2010;center study. Immun Inflamm Dis. 2021;9(4):1563&#x2010;1572. doi:10.1002/iid3.509</Citation></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks&#x2010;Manov N, et al. Long COVID outcomes at one year after mild SARS&#x2010;CoV&#x2010;2 infection: Nationwide cohort study. BMJ (Clin Res Ed.). 2023;380:e072529. doi:10.1136/bmj-2022-072529</Citation></Reference><Reference><Citation>F&#xfc;essl L, Lau T, Lean I, et al. Diminished short&#x2010; and long&#x2010;term antibody response after SARS&#x2010;CoV&#x2010;2 vaccination in hemodialysis patients. Vaccines. 2022;10(4):605. doi:10.3390/vaccines10040605</Citation></Reference><Reference><Citation>Dheir H, Tocoglu A, Toptan H, et al. Short and mid&#x2010;term SARS&#x2010;CoV&#x2010;2 antibody response after inactivated COVID&#x2010;19 vaccine in hemodialysis and kidney transplant patients. J Med Virol. 2022;94(7):3176&#x2010;3183. doi:10.1002/jmv.27714</Citation></Reference><Reference><Citation>Kim Y, Bae S, Chang HH, Kim SW. Long COVID prevalence and impact on quality of life 2 years after acute COVID&#x2010;19. Sci Rep. 2023;13(1):11207. doi:10.1038/s41598-023-36995-4</Citation></Reference><Reference><Citation>Zeng N, Zhao YM, Yan W, et al. A systematic review and meta&#x2010;analysis of long term physical and mental sequelae of COVID&#x2010;19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28(1):423&#x2010;433. doi:10.1038/s41380-022-01614-7</Citation></Reference><Reference><Citation>Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48(suppl 1):S2&#x2010;S90. doi:10.1053/j.ajkd.2006.03.051</Citation></Reference><Reference><Citation>Kooman JP, Carioni P, Kovarova V, et al. Modifiable risk factors are important predictors of COVID&#x2010;19&#x2010;related mortality in patients on hemodialysis. Front Nephrol. 2022;2:907959. doi:10.3389/fneph.2022.907959</Citation></Reference><Reference><Citation>Chen CY, Liu KT, Shih SR, et al. Adequacy of hemodialysis serves as an independent predictor of humoral response to ChAdOx1 prime&#x2010;boost vaccination in hemodialysis patients. Viruses. 2022;14(6):1149. doi:10.3390/v14061149</Citation></Reference><Reference><Citation>Silva RE, Santos EC, Justino PBI, et al. Cytokines and chemokines systemic levels are related to dialysis adequacy and creatinine clearance in patients with end&#x2010;stage renal disease undergoing hemodialysis. Int Immunopharmacol. 2021;100:108154. doi:10.1016/j.intimp.2021.108154</Citation></Reference><Reference><Citation>Lim YJ, Sidor NA, Tonial NC, Che A, Urquhart BL. Uremic toxins in the progression of chronic kidney disease and cardiovascular disease: Mechanisms and therapeutic targets. Toxins. 2021;13(2):142. doi:10.3390/toxins13020142</Citation></Reference><Reference><Citation>Stepanova N, Driianska V, Rysyev A, Ostapenko T, Kalinina N. IL&#x2010;6 and IL&#x2010;17 as potential links between pre&#x2010;existing hypertension and long&#x2010;term COVID sequelae in patients undergoing hemodialysis: A multicenter cross&#x2010;sectional study. Sci Rep. 2024;14(1):4968. doi:10.1038/s41598-024-54930-z</Citation></Reference><Reference><Citation>Asghar MS, Ahsan MN, Mal P, Tahir MJ, Yasmin F, Abbasher Hussien Mohamed Ahmed K. Assessment of quality of life determinants in hemodialysis patients of a developing country: A cross&#x2010;sectional study during ongoing COVID&#x2010;19 pandemic. Medicine. 2022;101(31):e29305. doi:10.1097/md.0000000000029305</Citation></Reference><Reference><Citation>Bayhakki, Utomo W, Dewi AP. Characteristics of patients undergoing hemodialysis during COVID&#x2010;19 pandemic. Enferm Clin. 2021;31:597&#x2010;600. doi:10.1016/j.enfcli.2021.04.020</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2010;631. doi:10.1038/s41591-021-01292-y</Citation></Reference><Reference><Citation>Luo J, Zhang J, Tang HT, et al. Prevalence and risk factors of long COVID 6&#x2010;12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong. J Med Virol. 2023;95(6):e28862. doi:10.1002/jmv.28862</Citation></Reference><Reference><Citation>Yong SJ, Halim A, Halim M, et al. Inflammatory and vascular biomarkers in post&#x2010;COVID&#x2010;19 syndrome: A systematic review and meta&#x2010;analysis of over 20 biomarkers. Rev Med Virol. 2023;33(2):e2424. doi:10.1002/rmv.2424</Citation></Reference><Reference><Citation>Lechuga GC, Morel CM, De&#x2010;Simone SG. Hematological alterations associated with long COVID&#x2010;19. Front Physiol. 2023;14:1203472. doi:10.3389/fphys.2023.1203472</Citation></Reference><Reference><Citation>Son K, Jamil R, Chowdhury A, et al. Circulating anti&#x2010;nuclear autoantibodies in COVID&#x2010;19 survivors predict long COVID symptoms. Eur Respir J. 2023;61(1):2200970. doi:10.1183/13993003.00970-2022</Citation></Reference><Reference><Citation>Chee YJ, Fan BE, Young BE, Dalan R, Lye DC. Clinical trials on the pharmacological treatment of long COVID: A systematic review. J Med Virol. 2023;95(1):e28289. doi:10.1002/jmv.28289</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>